WallStreetZenWallStreetZen

NASDAQ: NKTR
Nektar Therapeutics Stock Ownership - Who owns Nektar Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Nektar Therapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Howard W. RobinPresident CEO2026-02-18423$73.00
$30.88kSell
Jonathan ZalevskyChief RD Officer2026-02-18180$73.00
$13.14kSell
Jonathan ZalevskyChief RD Officer2026-01-203,867$35.67
$137.94kSell
Howard W. RobinPresident CEO2025-11-252,207$54.28
$119.80kSell
Mark Andrew WilsonChief Legal Officer2025-11-25630$54.28
$34.20kSell
Jonathan ZalevskyChief RD Officer2025-11-251,157$54.28
$62.80kSell
Howard W. RobinPresident CEO2025-09-092,100$45.16
$94.84kSell
Howard W. RobinPresident CEO2025-09-091,200$46.41
$55.69kSell
Howard W. RobinPresident CEO2025-09-092,156$47.49
$102.39kSell
Howard W. RobinPresident CEO2025-09-091,210$48.18
$58.30kSell

1 of 3

NKTR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NKTR insiders and whales buy or sell their stock.

NKTR Shareholders

What type of owners hold Nektar Therapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Deep Track Capital LP63.94%18,344,000$1.37BInsider
John Stuart Patton10.40%2,984,703$223.38MInsider
Bvf Inc5.44%1,559,595$116.72MInstitution
Vanguard Group Inc3.58%1,027,089$76.87MInstitution
Two Seas Capital LP2.60%745,185$55.77MInstitution
Blackrock Inc2.25%645,607$48.32MInstitution
Armistice Capital LLC2.08%596,000$44.60MInstitution
Ajit Gill2.02%578,645$43.31MInsider
Morgan Stanley1.97%566,421$42.39MInstitution
Prosight Management LP1.93%554,633$41.51MInstitution

1 of 3

NKTR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NKTR41.27%58.73%Net SellingNet Selling
CLDX85.25%14.75%Net BuyingNet Buying
ADPT62.97%37.03%Net SellingNet Selling
GLPG47.64%0.00%
SNDX91.46%8.54%Net SellingNet Selling
View Top Biotech Stocks

Nektar Therapeutics Stock Ownership FAQ

Who owns Nektar Therapeutics?

Nektar Therapeutics (NASDAQ: NKTR) is owned by 60.37% institutional shareholders, 85.90% Nektar Therapeutics insiders, and 0.00% retail investors. Deep Track Capital LP is the largest individual Nektar Therapeutics shareholder, owning 18.34M shares representing 63.94% of the company. Deep Track Capital LP's Nektar Therapeutics shares are currently valued at $1.32B.

If you're new to stock investing, here's how to buy Nektar Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.